Skip to content

Contact +44 (0) 20 7060 7474 email us

Drug Delivery

Drug Delivery Technologies: Players, products & prospects to 2015

 

Publication Date November 2007
Publisher Espicom
Product Type Report
Pages 454
ISBN Number 978-1-85822-302-5
Product Code ESP01046

Price

£1,795.00
approximately: $2,675 | €1,969

pdf

Buy Now

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry's future and critical to bringing novel therapies to market.

Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. Despite the importance of the sector the pharmaceutical industry has not always been quick to embrace the full range of potential technologies and opportunities.

With so many companies pursuing a wide range of research strategies, it is difficult for industry and commercial executives to get a balanced and independent overview of the competitive landscape.

That is why this major new 4-volume report, Drug Delivery Technology: Players, products and prospects to 2015, is essential reading for everyone in the field, from niche technology specialists through to the investment community and the pharmaceutical industry itself.

By 2015 sales of products using drug delivery technology assessed in this report could exceed US$43 billion.

  • This report provides a detailed insight into the current and future market for drug delivery technology and...
  • Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed.
  • Appraises currently available products which utilise drug delivery technology and assesses their future.
  • Examines new product development among major specialist drug delivery companies, critically analysing the prospects at the product level and forecasting sales.
  • Allows ready comparison on different technologies within a company's portfolio.
  • Provides a unique window on the sector's product launch timetable
  • Includes detailed appendices which allow at-a-glance reviews of the competitive landscape for both new and up and coming products.

Use this report to...

  • Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies;
  • Identify and review licencing and collaboration partners;
  • Understand the merits and applications of the main approaches being researched; and, Quantify the commercial prospects for current and future products.

Unique company & technology evaluation

It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.

In this report we present a prcis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:

  • Proprietary delivery technology;
  • Applications of the delivery technology within the pharma industry;
  • Management/technical expertise of the delivery specialist;
  • Competition within the delivery technology sector; and,
  • Products in development/approved utilising the delivery technology.

We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom "ranking table" in each segment of the market, dependent on their relative attributes.

  • Multi-point evaluation and scoring assessment
  • Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
  • The technology
  • Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
  • The application of the technology within a number of therapy areas
  • Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
  • The current status of the technology in clinical development or following approval
  • Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products
  • Competition within the technology arena
  • Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors
  • The drug delivery specialist's expertise
  • Number of drug delivery systems in development, strategic alliances, financial position, marketing presence
  • The product portfolio
  • Drug delivery systems under evaluation, products in development, commercialisation/developmental partnerships
  • Potential drug sales
  • Based on key events such as market, competition, patent expiry, time of entry into the market

Providing

  • Critical analyses and competitive ratings for major specialist developers
  • Unique sales forecasts to 2015 for key current and new products utilising drug delivery technologies
  • A comprehensive examination of the 4 major and compelling drug delivery sectors

While pharmaceutical sales have continued to rise steadily during the last five years generating over US$600 billion in 2006, the global drug delivery market has undergone rapid growth from an estimated US$26 billion in 2000 to approximately US$67 billion in 2006. This market has been driven by a number of factors including:

  • Patent expiration of leading brands forcing the pharmaceutical industry to evaluate ways to maximize product life-cycles through new formulations, combinations and repositioning;
  • Advances in new delivery technology (microencapsulation and nanotechnology); and
  • The development and cost-effective manufacture of new delivery materials (dendrimers, lipid formulations and biodegradable polymers).

Within this market there are a number of areas of advanced drug delivery which have attracted the attention of pharmaceutical industry and the investment community. The dramatic growth of the sector is reflected in the evolution of an array of delivery vehicles and hybrid platforms that are increasingly being used to deliver approved and novel therapeutic agents.

Focusing on the sectors that are driving growth!

  • Volume I
  • Controlled- Release Delivery
  • Volume Ii
  • Nano-Enabled Delivery
  • Volume Iii
  • Nucleic Acid Delivery
  • Volume Iv
  • Targeted Delivery

Few sectors of the pharmaceutical industry will enjoy such a high level of growth in the future.

Contents

  • Part 1 Nucleic Acid Delivery
    • Executive Summary
      • Competitor Ratio Analysis Summary
    • Introduction
      • Overview Of Delivery Technologies For Genetic Material: Past, Prese Nt & Future
      • Nucleic Acid Delivery: Motivators & Resistors
      • Motivators
      • Resistors
    • Nucl Eicacid Deliv Ery Technologies
      • Types Of Nucleic Acid Based Products Under Development By The Pharma Industry
      • Viral Vector Delivery Of Nucleic Acids
        • Figure 1: Schematic Of Gene Therapy Utilising An Aav Vector
        • Figure 2: Schematic Of Gene Therapy Utilising Hvj Envelope - Virosome
      • Non-Viral Vector Delivery Of Nucleic Acids
        • Figure 3: Stable Nucleic Acid-Lipid Particles
        • Figure 4: Targeted Nanoparticles
        • Figure 5: Schematic Of Macroflux Technology
        • Figure 6: Schematic Of Pmed Technology And Delivery
      • Table 1: Advantages And Disadvantages Of Nucleic Acid Platforms
      • Current Therapeutic Applications For The Viral And Non-Viral Delivery Of Nucleic Acids
      • Leading Nucleic Acid Based Products In Development
      • Table 2: Nucleic Acid-Based Approved/Filed Drugs
      • Table 3: Selection Of Nucleic Acid-Based Developmental Drugs
      • Future Commercial Applications & Opportunities
      • Strat Egi Es Of Drug Deliv Ery Compani Es
      • Leading Nucleic Acid Drug Delivery Companies
      • Table 4: Leading Nucleic Acid Drug Delivery Specialists
      • Partnerships & Acquisitions
      • Strategic Developmental & Commercialisation Partnerships
      • Mergers & Acquisitions
      • Table 5: Recent Partnerships & Acquisitions In The Nucleic Acid Field
      • Intellectual Property
      • Table 6: Nucleic Acid Patents
      • Th E Viral And Non-Viral Vector De Livery Mar Ket
      • Now 2007
      • Table 7: Approved Nucleic Acid Product Sales
      • Future 2015
      • Table 8: Global Controlled-Release Product Sales
      • Table 9: Novel Nucleic Acid Product Sales
      • Comp Etitor Analy Sis
      • Movers & Shakers: Cutting Edge Or Losing Their Grip
      • Table 10: Movers & Shakers In Nucleic Acid Drug Delivery Systems
      • Company Profil Es
      • Alphavax, Inc. (Www.Alphavax.Com)
      • Figure 7: The Alphavaccine Platform System
      • Table 11: Alphavax Product Pipeline
      • Table 12: Alphavax' Sales Forecasts (Us$ Million)
      • Altea Therapeutics, Inc. (Www.Alteatherapeutics.Com)
      • Table 13: Altea Therapeutics' Product Pipeline
      • Ap Pharma, Inc (Www.Appharma.Com)
      • Table 14: Ap Pharma's Product Pipeline
      • Aradigm, Inc (Www.Aradigm.Com)
      • Table 15: Aradigm's Product Pipeline
      • Biodelivery Sciences International (Www.Biodeliverysciences.Com)
      • Figure 8: Bioral Technology
      • Figure 9: Direct Membrane Fusion
      • Table 16: Bdsi's Product Pipeline
      • Calando Pharmaceuticals (Www. Calandopharma.Com)
      • Figure 10: Schematic Of Cyclodextrin Polymeric Nanoparticles
      • Table 17: Calando's Product Pipeline
      • Table 18: Calando's Sales Forecasts
      • Copernicus Therapeutics (Www.Cgsys.Com)
      • Figure 11: Uptake And Trafficking Of Condensed Nanoparticle Dna
      • Table 19: Copernicus' Product Pipeline
      • Table 20: Copernicus' Sales Forecasts
      • Diatos Sa (Www.Diatos.Com)
      • Table 21: Diatos' Product Pipeline
      • Dor Biopharma, Inc (Www.Dorbiopharma.Com)
      • Table 22: Dor's Product Pipeline
      • Expression Genetics, Inc (Www.Egencorp.Com)
      • Figure 12: Theraplas Technology Platform
      • Table 23: Egen's Product Pipeline
      • Table 24: Egen's Sales Forecasts
      • Inovio Biomedical Corporation (Www.Inovio.Com)
      • Figure 13: Inovio's Gene Delivery Platform
      • Table 25: Inovio's Product Pipeline
      • Table 26: Inovio's Sales Forecasts
      • Macroflux Corporation (Www.Macroflux.Com)
      • Table 27: Macroflux' Product Pipeline
      • Maxcyte, Inc (Www.Maxcyte.Com)
      • Figure 14: Maxcyte's Gt Ex-Vivo Cell Loading System
      • Table 28: Maxcyte's Product Pipeline
      • Mirus Bio Corporation (Www.Mirusbio.Com)
      • Figure 15: Polyconjugates - Sirna Delivery System
      • Table 29: Mirus' Product Pipeline
      • Table 30: Mirus' Sales Forecasts
      • Nanotherapeutics Inc. (Www.Nanotherapeutics.Com)
      • Table 31: Nanotherapeutics' Product Pipeline
      • Neopharm (Www.Neopharm.Com)
      • Table 32: Neopharm's Product Pipeline
      • Novagali Pharma Sa (Www.Novagali.Com)
      • Table 33: Novagali's Product Pipeline
      • Pci Biotech (Www.Pcibiotech.Com)
      • Table 34: Pci's Product Pipeline
      • Powdermed Inc (Www.Powdermed.Com)
      • Table 35: Powdermed's Product Pipeline
      • Table 5.2.25: Powdermed's Sales Forecasts
      • Protiva Biotherapeutics, Inc (Www.Protivabio.Com)
      • Table 37: Protiva's Product Pipeline
      • Table 38: Protiva's Sales Forecasts
      • Silence Therapeutics Plc (Www.Silence-Therapeutics.Com)
      • Drug Delivery Technologies
      • Table 39: Silence Therapeutics' Product Pipeline
      • Table 40: Silence Therapeutics' Sales Forecasts
      • Supratek Pharma Inc. (Www.Supratek.Com)
      • Table 40: Supratek's Product Pipeline
      • Tekmira Pharmaceuticals Corporation (Www.Tekmirapharm.Com)
      • Table 42: Tekmira's Product Pipeline
      • Table 43: Tekmira's Sales Forecasts
      • Vical Inc. (Www.Vical.Com)
      • Table 44: Vical's Product Pipeline
      • Table 45: Vical's Sales Forecasts
    • Appendix 1
      • Table 46: Global Nucleic Acid Approved Drugs Sales 2006a-20015e
    • Apendix 2
      • Table 47: Global Nucleic Acid Developmental Drugs Sales 2006a-20015e
    • Appendix 3
      • Competitor Ratio Analysis Criteria
      • Table 48: Key Nucleic Acid Delivery Companies By 2015
    • Bibliography
    • Glossary
    • Acronym S
    • Fotnot E Referenc Es
  • Part 2 Controlled-Release
    • Executive Summary
      • Competitor Ratio Analysis Summary
    • Introduction
      • Overview Of Contr Olled-Re Lease Delivery : Past , Prese Nt & Future
      • Controlled-Release Delivery: Motivators & Resistors
      • Motivators
      • Resistors
      • Controlled-Release Delivery: Impact On Product Lifecycles
      • Con Troll Ed-Release Delivery
      • Types Of Controlled-Release Delivery Used By Pharma Industry
      • Activated Controlled-Release Delivery
      • Figure 1: Activated Controlled-Release Delivery - Alza's Oros Systems
      • Degradation Controlled-Release Delivery
      • Figure 2: Degradation Controlled-Release Delivery - Skyepharma's Geomatrix
      • Diffusion Controlled-Release Delivery
      • Figure 3: Monolithic Diffusion Controlled-Release Delivery - Labopharm's Contramid
      • Figure 4: Reservoir Diffusion Controlled-Release Delivery - Impax' Cmds
      • Figure 5: Combined Controlled-Release Delivery - Flamel's Micropump
      • Table 1: Advantages And Disadvantages Of Controlled-Release Platforms
      • Current Therapeutic Application Of Controlled-Release In Drug Delivery
      • Leading Brands That Utilise Controlled-Release Delivery
      • Table 2: Controlled-Release Approved Drugs
      • Future Commercial Applications & Opportunities
      • Strategies Of Drug Delivery Companies
      • Leading Controlled-Release Drug Delivery Companies
      • Table 3: Leading Controlled-Release Drug Delivery Companies
      • Partnerships & Acquisitions
      • Strategic Developmental & Commercialisation Partnerships
      • Merger & Acquisitions
      • Table 4: Recent Partnerships & Acquisitions In The Controlled-Release Field
      • Intellectual Property
      • Table 5: Controlled-Release Patents
      • The Controlled-Release Market Now 2007
      • Table 6: Approved Controlled-Release Product Sales
      • Future 2015
      • Table 7: Global Controlled-Release Product Sales
      • Table 8: Novel Controlled-Release Product Sales
      • Competitor Analysis
      • Movers & Shakers: Cutting Edge Or Losing Their Grip
      • Table 9: Movers & Shakers In Controlled-Release Drug Delivery Systems
      • Company Prof Iles
      • Alpharx Corporation (Www.Alpharx.Com)
      • Table 10: Alpharx' Product Pipeline
      • Table 11: Alpharx' Drug Delivery Sales
      • Alza Corporation (Www.Alza.Com)
      • Table 12: Alza's Product Pipeline
      • Table 13: Alza's Drug Delivery Sales
      • Andrx Corporation (Www.Watsonandandrx.Com)
      • Table 14: Andrx' Product Pipeline
      • Table 15: Andrx' Drug Delivery Sales
      • Antares Pharma, Inc. (Www.Antarespharma.Com)
      • Table 16: Antares' Product Pipeline
      • Table 17: Antares' Drug Delivery Sales
      • Biovail International (Www.Biovail.Com)
      • Table 18: Biovail's Product Pipeline
      • Table 19: Biovail's Drug Delivery Sales
      • Camurus Ab (Www.Camurus.Se)
      • Table 20: Camurus Ab's Product Pipeline
      • Table 21: Camurus Ab's Drug Delivery Sales
      • Cipher Pharmaceuticals, Inc. (Www.Cipherpharma.Com)
      • Table 22: Cipher's Product Pipeline
      • Table 23: Cipher's Drug Delivery Sales
      • Debiopharm (Www.Debio.Com)
      • Table 24: Debiopharm's Product Pipeline
      • Table 25: Debiopharm's Drug Delivery Sales
      • Delsite Biotechnologies, Inc. (Www.Delsite.Com)
      • Table 26: Delsite's Product Pipeline
      • Depomed, Inc. (Www.Depomedinc.Com)
      • Table 27: Depomed's Product Pipeline
      • Table 28: Depomed's Product Sales
      • Durect Corporation (Www.Durect.Com)
      • Table 29: Durect's Product Pipeline
      • Table 30: Durect's Product Sales
      • Eiffel Technologies (Www.Eiffeltechnologies.Com.Au)
      • Table 31: Eiffel's Product Pipeline
      • Elan Corporation (Www.Elan.Com)
      • Table 32: Elan's Product Pipeline
      • Table 33: Elan's Drug Delivery Sales
      • Elite Pharmaceuticals, Inc. (Www.Elitepharma.Com)
      • Table 34: Elite's Product Pipeline
      • Table 35: Elite's Product Sales
      • Endo Pharmaceuticals, Inc. (Www.Endo.Com)
      • Table 36: Endo's Product Pipeline
      • Table 37: Endo's Product Sales
      • Ethypharm Sa (Www.Ethypharm.Com)
      • Table 38: Ethypharm's Product Pipeline
      • Table 39: Ethypharm's Product Sales
      • Eurand (Www.Eurand.Com)
      • Table 40: Eurand's Product Pipeline
      • Table 41: Eurand's Product Sales
      • Flamel Technologies, Inc. (Www.Flamel.Com)
      • Table 42: Flamel's Product Pipeline
      • Table 43: Flamel's Product Sales
      • Glycologic, Ltd (Www.Glycologic.Co.Uk)
      • Table 44: Glycologic's Product Pipeline
      • Impax Laboratories, Inc. (Www.Impaxlabs.Com)
      • Table 45: Impax' Product Pipeline
      • Table 46: Impax's Product Sales
      • Kv Pharmaceuticals, Inc (Www.Kvpharmaceutical.Com)
      • Table 47: Kv's Product Pipeline
      • Labopharm, Inc. (Www.Labopharm.Com)
      • Table 48: Labopharm's Product Pipeline
      • Table 49: Labopharm's Product Sales
      • Lavipharm Sa (Www.Lavipharm.Com)
      • Table 50: Lavipharm's Product Pipeline
      • Table 51: Lavipharm's Product Sales
      • Octoplus N.V. (Www.Octoplus.Nl)
      • Table 52: Octoplus' Product Pipeline
      • Table 53: Octoplus' Product Sales
      • Penwest Pharmaceuticals (Www.Penw.Com)
      • Table 54: Penwest's Product Pipeline
      • Table 55: Penwest's Product Sales
      • Protherics (Www.Protherics.Com)
      • Table 56: Protherics' Product Pipeline
      • Table 57: Protherics' Drug Delivery Sales
      • Scol R Pharma, Inc. (Www.Scolr.Com)
      • Table 58: Scolr's Product Pipeline
      • Table 59: Scolr's Drug Delivery Sales
      • Shire (Www.Shire.Com)
      • Table 60: Shire's Product Pipeline
      • Table 61: Shire's Drug Delivery Sales
      • Skinvisible, Inc. (Www.Skinvisible.Com)
      • Table 62: Skinvisible's Product Pipeline
      • Skyepharma (Www.Skyepharma.Com)
      • Table 63: Skyepharma's Cr Product Pipeline
      • Table 64: Skyepharma's Controlled-Release Product Sales
      • Spherics (Www.Spherics.Com)
      • Table 65: Spheric's Product Pipeline
    • Appendix 1
      • Table 66: Global Controlled-Release Approved Drugs Sales 2006a-20015e
    • Appendix 2
      • Table 67: Global Controlled-Release Developmental Drugs Sales 2006a-20015e
    • Appendix 3
      • Competitor Ratio Analysis Criteria
      • Table 68: Key Controlled-Release Delivery Companies By
    • Bibliography
    • Glo Ssary
    • Acronyms
  • Part3 Nanotechnology
    • Executive Summary
      • Competitor Ratio Analysis Summary
    • Introduction
    • Overview Of Nanotechnology: Past, Prese Nt & Future
      • Figure 1: Top Ten Applications Of Nanotechnology In Developing Countries
    • Nanotechnology: Motivators & Resistors
      • Motivators
      • Resistors
      • Nanotechnology: Impact On Product Lifecycles
      • Nanot Echnology In Drug Deliv Ery
      • Core Nanotechnology Used By The Pharma Industry
      • Nano-Engineered Drugs
      • Nano-Carriers
      • Figure 2: Dendrimer Structure
      • Figure 3: Liposome Structure
      • Figure 4: Micelle Structure
      • Current Therapeutic Application Of Nanotechnology In Drug Delivery
      • Leading Brands That Utilise Nanotechnology Delivery
      • Table 1: Nanotechnology-Enabled Approved Drugs
      • Future Commercial Applications & Opportunities
    • Strategies Of Drug Delivery Companies
      • Leading Nanotechnology Drug Delivery Companies
      • Table 2: Leading Nanotechnology-Enabled Drug Delivery Companies
      • Partnerships & Acquisitions
      • Strategic Development & Commercialisation Partnerships And Joint Ventures
      • Table 3: Recent Partnerships & Acquisitions In The Nanotechnology Field
      • Mergers & Acquisitions
      • Table 4: Nanotechnology Patents
    • The eanot Echnology Market
      • Now 2007
      • Table 5: Approved Nano-Enabled Product Sales
      • Future
      • Table 6: Novel Nano-Enabled Product Sales
      • Table 7: Global Nano-Enabled Product Sales
      • Comp Etitor Analy Sis
      • Movers & Shakers: Cutting Edge Or Losing Their Grip
      • Table 8: Movers & Shakers In Nanotechnology Drug Delivery Systems
      • Company Profiles
      • Abraxis Bioscience (Www.Abraxisbio.Com)
      • Table 9: Abraxis' Product Pipeline
      • Table 10: Abraxis Drug Delivery Sales
      • Access Pharmaceuticals (Www.Accesspharma.Com)
      • Table 11: Access Pharmaceuticals Product Pipeline
      • Alpharx Corporation (Www.Alpharx.Com)
      • Table 12: Alpharx' Product Pipeline
      • Table 13: Alpharx' Pharmaceuticals Drug Delivery Sales
      • Al Za Corporation (Www.Alza.Com)
      • Table 14: Alza's Drug Delivery Sales
      • Biosante Pharmaceuticals (Www.Biosantepharma.Com)
      • Pipeline
      • Table 16: Biosante's Drug Delivery Sales
      • Camurus Ab (Www.Camurus.Se)
      • Table 17: Camurus Ab's Product Pipeline
      • Table 18: Camurus Ab's Drug Delivery Sales
      • Eiffel Technologies (Www.Eiffeltechnologies.Com)
      • Table 19: Eiffel's Product Pipeline
      • Elan Corporation (Www.Elan.Com)
      • Table 20: Elan's Product Pipeline
      • Table 21: Elan's Drug Delivery Sales
      • Eurand (Www.Eurand.Com)
      • Table 22: Eurand's Product Pipeline
      • Gilead Sciences (Www.Gilead.Com)
      • Table 23: Gilead Sciences' Product Pipeline
      • Table 24: Gilead Sciences' Drug Delivery Sales
      • Nano Interface Technology (Www.Nanointerfacetech.Com)
      • Table 25: Niti's Product Pipeline
      • Nano S Biotechnology Gmbh (Www.Nano-S.Com)
      • Table 26: Nano S' Product Pipeline
      • Nanobio Corporation (Www.Nanobio.Com)
      • Table 27: Nanobio's Product Pipeline
      • Table 28: Nanobio's Drug Delivery Sales
      • Nanobiomagnetics (Www.Nanobmi.Com)
      • Table 29: Nanobiomagnetics' Product Pipeline
      • Nanobiotix (Www.Nanobiotix.Com)
      • Table 30: Nanobiotix' Product Pipeline
      • Nanocarrier (Www.Nanocarrier.Co.Jp)
      • Table 31: Nanocarrier's Product Pipeline
      • Table 32: Nanocarrier's Drug Delivery Sales
      • Nanotechnology Victoria, Ltd (Www.Nanovic.Com)
      • Table 33: Nanovic's Product Pipeline
      • Nanomaterials Technology (Www.Nanomt.Com)
      • Table 34: Nanomaterial's Product Pipeline
      • Nanotherapeutics (Www.Nanotherapeutics.Com)
      • Table 35: Nanotherapeutics' Product Pipeline
      • Table 36: Nanotherapeutics' Drug Delivery Sales
      • Novavax (Www.Novavax.Com)
      • Table 37: Novavax's Product Pipeline
      • Table 38: Novavax's Drug Delivery Sales
      • Skyepharma (Www.Skyepharma.Com)
      • Table 39: Skyepharma's Product Pipeline
      • Table 40: Skyepharma's Product Sales
      • Spherics (Www.Spherics.Com)
      • Table 41: Spheric's Product Pipeline
    • Appendix 1
      • Table 42: Global Nanotechnology Approved Drugs Sales 2006a-20015e
    • Appeendix 2
      • Table 43: Global Nanotechnology Developmental Drugs Sales 2006a-20015e
    • Appendix 3
      • Competitor Ratio Analysis Criteria
      • Table 44: Key Nanotechnology Delivery Companies By
    • Bibliography
    • Glossary
    • Acronyms
  • Part 4 Systemic Targeted Delivery
    • Executive Summary
      • Competitor Ratio Analysis Summary
    • Introduction
      • Overview of delivery technologies for systemic targeted delivery: past, present & future
    • Systemic targeted delivery: motivators & resistors
      • Motivators
      • Resistors
      • Systemic targeted
    • Delivery Technologies
      • Types of systemic targeted delivery platform in development in the pharma industry
      • Targeting ligands
        • Figure 1: Antibody-directed enzyme prodrug targeted delivery
        • Figure 2: Peptide-induced release for targeted delivery
        • Figure 3: Nucleomic mediated targeted intranuclear delivery
        • Figure 4: Vitamin mediated targeted intracellular delivery - Cobalamin Non-biological targeting platforms
        • Figure 5: Photosensitive targeted delivery
      • Current therapeutic applications for systemic targeted delivery
      • Leading systemic targeted products in development
      • Table 1: Approved systemic and targeted drugs
      • Future commercial applications & opportunities
      • STRAT EGI ES OF DRUG DELIV ERY COMPANI ES
      • Leading targeted drug delivery companies
      • Table 2: Leading systemic targeted delivery specialists
      • Partnerships & acquisitions
      • Strategic alliances
      • Strategic acquisitions
      • Table 3: Recent market activity in targeted delivery companies
      • Intellectual Property
      • Table 4: Targeted drug delivery patents
      • TH E TARG ETED De livery MAR KET
      • Now 2007
      • Table 5: Approved targeted delivery product sales
      • Future
      • Table 6: Global controlled release product sales
      • Table 7: Novel targeted delivery product sales
    • Competitor Analysis
      • Movers & Shakers: Cutting edge or losing their grip
      • Table 8: Movers & shakers in targeted drug delivery systems
    • Company Profiles
      • Access Pharmaceuticals (www.accesspharma.com)
      • Figure 6: Schematic of targeted nanoparticle
      • Table 9: Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers
      • Table 10: Access Pharmaceuticals' product pipeline
      • Table 11: Access Pharmaceuticals' targeted delivery sales forecasts
      • AL ZA (www.alza.com)
      • Table 12: ALZA's product pipeline
      • Table 13: ALZA's targeted drug delivery sales
      • Avidimer Therapeutics (www.avidimer.com)
      • Table 14: Avidimer's product pipeline
      • Table 15: Avidimer's targeted drug delivery sales
      • Calando Pharmaceuticals (www. calandopharma.com)
      • Figure 7: Schematic of cyclodextrin polymeric nanoparticles
      • Table 16: Calando's product pipeline
      • Table 17: Calando's targeted delivery sales forecasts
      • Cell Therapeutics (www.ctiseattle.com)
      • Figure 8: CTI's polyglutamate polymer technology
      • Table 18: CTI's product pipeline
      • Copernicus Therapeutics (www.cgsys.com)
      • Table 20: Copernicus' product pipeline
      • Table 21: Copernicus' targeted delivery sales forecasts
      • Diatos SA (www.diatos.com)
      • Table 22: Diatos' product pipeline
      • Table 23: Diatos' targeted drug delivery sales
      • Enzon Pharmaceuticals, Inc. (www.enzon.com)
      • Table 24: Enzon's product pipeline
      • Table 25: Enzon's targeted product sales
      • Endocyte Inc. (www.endocyte.com)
      • Table 26: Endocyte's product pipeline
      • Table 27: Endocyte's targeted drug delivery sales
      • Eurand (www.eurand.com)
      • Table 28: Eurand's product pipeline
      • ImmunoGen (www.immunogen.com)
      • Table 29: ImmunoGen's product pipeline
      • Table 30: ImmunoGen's targeted delivery sales
      • ImaRx Therapeutics (www.imarx.com)
      • Table 31: ImaRx' product pipeline
      • Table 32: ImaRx' targeted product sales
      • Insert Therapeutics (www.insertt.com)
      • Figure 9: Schematic of Cyclosert's nanoparticle mediated drug delivery to solid tumours
      • Table 33: Insert Therapeutics' product pipeline
      • Table 34: Insert Therapeutics' targeted product sales
      • Mirus Bio Corporation (www.mirusbio.com)
      • Figure 10: PolyConjugates - siRNA delivery system
      • Table 35: Mirus' product pipeline
      • NanoBioMagnetics, Inc (www.nanobmi.com)
      • Table 36: NanoBioMagnetics' product pipeline
      • Nanobiotix (www.nanobiotix.com)
      • Table 37: Nanobiotix' product pipeline
      • NanoCarrier (www.nanocarrier.co.jp)
      • Figure 11: NanoCoat technology
      • Table 38: NanoCarrier's product pipeline
      • Table 39: NanoCarrier's targeted drug delivery sales
      • NeoPharm (www.neopharm.com)
      • Table 40: NeoPharm's product pipeline
      • Table 41: NeoPharm's drug delivery sales
      • Novosom AG (www.novosom.com)
      • Figure 12: Schematic of SMARTICLES mechanism of targeted delivery
      • Table 42: Novosom's product pipeline
      • PCI Biotech AS (www.photocure.com)
      • Drug Delivery Technologies
      • Figure 13: Schematic of principle of PCI technology
      • Table 43: PCI's product pipeline
      • Point BioMedical Corporation (www.pointbio.com)
      • Figure 14: Schematic of Point's biSphere
      • Table 44: Point's product pipeline
      • Quest PharmaTech (www.questpharmatech.com)
      • Table 45: Quest PharmaTech's product pipeline
      • Seattle Genetics (www.seattlegenetics.com)
      • Figure 15: Schematic of ADC's
      • Table 46: Seattle Genetic's product pipeline
      • Table 47: Seattle Genetic's delivery sales
      • Starpharma (www.starpharma.com)
      • Table 48: Starpharma's product pipeline
      • Supratek Pharma Inc. (www.supratek.com)
      • Table 49: Supratek's product pipeline
      • Tekmira Pharmaceuticals Corporation (www.tekmirapharm.com)
      • Table 50: Tekmira's product pipeline
      • Table 51: Tekmira's targeted delivery sales forecasts
    • Appendix 1
      • Table 52: Global targeted approved drugs sales 2006A-20015E
    • Appendix 2
      • Table 53: Global targeted developmental drugs sales 2006A-20015E
    • Appendix 3
      • Competitor Ratio Analysis Criteria
      • Table 54: Key targeted delivery companies by
    • Bibliography
    • Glossary
    • Acronyms